FOLR1-targeted deoxyribozyme enhanced the sensitivity of nasopharyngeal carcinoma xenografted tumor to paclitaxel
ZHANG Jie1, SU Xueping2, YANG Zifei1, WU Xianmin1, LI Heqing3
1.Department ofOtolaryngology-Head and Neck Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou325015, China; 2.Department of Otolaryngology-Head and Neck Surgery, the First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China; 3.Department of Otolaryngology-Head and Neck Surgery, the Third Xiangya Hospital of Central South University, Changsha 410013, China
ZHANG Jie,SU Xueping,YANG Zifei, et al. FOLR1-targeted deoxyribozyme enhanced the sensitivity of nasopharyngeal carcinoma xenografted tumor to paclitaxel[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2024, 54(2): 128-134.
Abstract：Objective: To investigate whether taxol sensitivity of nasopharyngeal carcinoma (NPC) grafts in nude mice could be enhanced by FOLR1- targeted deoxyribozyme (DrzE). Methods: NPC parent cells—CNE-1 cells and paclitaxel-resistant CNE-1/taxol cells were used for tumor formation experiment in nude mice.Then, the inhibition difference of NPC xenografted tumors was compared after receiving FOLR1-targeted DrzE alone and the combination of DrzE and paclitaxel. RT-qPCR and Western blot were used to detect the expression of FOLR1 in tumors before and after treatment. Results: CNE-1 tumors grew faster and larger than CNE-1/taxol transplanted tumors (P<0.05). Paclitaxel alone could inhibit the growth of CNE-1 transplanted tumor, but had no effect on paclitaxel-resistant tumors. Both CNE-1 and CNE-1/taxol transplanted tumors were inhibited by deoxyribozyme DrzE alone, and the inhibitory effect on the paclitaxel-resistant tumors was more significant(P<0.05). The combination of paclitaxel and deoxyribozyme had more significant inhibitory effect on the transplanted tumors than either drug alone (P<0.05). The expression of FOLR1 in CNE-1/taxol transplanted tumor before treatment was significantly higher than that in CNE-1 (P<0.01). Meanwhile, the expression of FOLR1 in DrzE group and the DrzE-paclitaxel group was significantly lower after treatment than that in the control group(P<0.05). Conclusion: The transfection of deoxyribozyme DrzE targeting FOLR1 in the transplanted tumor of nude mice can reduce the proliferation rate of nasopharyngeal carcinoma and increase the sensitivity of drugresistant transplanted tumor to paclitaxel.
